Stoke Therapeutics Inc (STOK) - Total Liabilities
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has total liabilities worth $48.40 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Stoke Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See STOK net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Stoke Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Stoke Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pharvaris BV
NASDAQ:PHVS
|
USA | $26.66 Million |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
China | CN¥3.55 Billion |
|
Firstsource Solutions Limited
NSE:FSL
|
India | Rs42.95 Billion |
|
Allied Machinery Co. Ltd.
SHG:605060
|
China | CN¥546.67 Million |
|
Hunan Kaimeite Gases Co Ltd
SHE:002549
|
China | CN¥811.31 Million |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
China | CN¥212.98 Million |
|
Megaport Ltd
AU:MP1
|
Australia | AU$437.11 Million |
|
Omnicell Inc
NASDAQ:OMCL
|
USA | $742.91 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Stoke Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see STOK market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stoke Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Stoke Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.98 Million | +55.12% |
| 2024-12-31 | $42.53 Million | -38.16% |
| 2023-12-31 | $68.78 Million | -3.43% |
| 2022-12-31 | $71.22 Million | +237.72% |
| 2021-12-31 | $21.09 Million | +78.00% |
| 2020-12-31 | $11.85 Million | +174.11% |
| 2019-12-31 | $4.32 Million | +74.91% |
| 2018-12-31 | $2.47 Million | -33.77% |
| 2017-12-31 | $3.73 Million | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more